Cancer immunotherapy reactivates the immune function of immune cells by blocking immune checkpoints (e.g., programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4)) and restores the anti-tumor activity of immune cells [2, 3]. Here, CTLA4 is linked to cancer.